T regulatory cells (Tregs) are subsets of T lymphocytes specialized in modulating antigen-specific immune responses in vivo. Hence, Tregs represent an ideal therapeutic tool to control detrimental immune reactions. Based on solid pre-clinical results, investigators started testing the safety and efficacy of Treg-based therapies in humans. Despite promising results, a number of issues remain to be solved. We will discuss the results obtained from clinical trials and the challenges and risks we are facing in the further development of Treg-based therapies.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4658444 | PMC |
| http://dx.doi.org/10.3389/fimmu.2015.00593 | DOI Listing |
Publication Analysis
Top Keywords
treg-based therapies
8
clinical outlook
4
outlook type-1
4
type-1 foxp3+
4
foxp3+ regulatory
4
regulatory cell-based
4
cell-based therapy
4
therapy regulatory
4
regulatory cells
4
cells tregs
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!